In partnership with
December 30, 2025
Built by a former cannabis regulator, Policy, Decoded helps operators read the policy terrain before it shifts beneath their feet.
Ohio is living the problem in real time: courts, a veto, a referendum drive, and a federal hemp rewrite all running on different timelines. Washington is moving again too, with Schedule III pressure and a fresh push to revisit hemp-derived CBD, which keeps the federal line unsettled.
Today’s edition is supported by 1440 Media and The Rundown. To sponsor Policy, Decoded and reach the executives, investors, and policymakers who read this briefing, reply to this email and we will send details.
🧾 Three clocks, one market
⚖️ Process drives the outcome
🧠 Compliance gets expensive fast
Keep it disciplined. The rent comes due either way.
Looking for unbiased, fact-based news? Join 1440 today.
Join over 4 million Americans who start their day with 1440 – your daily digest for unbiased, fact-centric news. From politics to sports, we cover it all by analyzing over 100 sources. Our concise, 5-minute read lands in your inbox each morning at no cost. Experience news without the noise; let 1440 help you make up your own mind. Sign up now and invite your friends and family to be part of the informed.
Start here — the day’s most important development, decoded for impact.
🧾 Context: Ohio has spent the last year trying to get intoxicating hemp under control (despite it already being legal), and the route has been a full tour of American government. Governor DeWine pushed an executive order. Courts pulled the leash back. Lawmakers wrote legislation to make the restrictions stick, with exceptions. While Ohio was doing that, Congress rewrote the federal hemp definition in a November funding bill and put a November 2026 effective date on a finished-product cap that threatens most intoxicating formats in national commerce. The legislature still tried to give bars and compliant sellers a small beverage off-ramp so they could transition without losing their shirts. DeWine vetoed it. Now advocates are gathering signatures to freeze the law and force a statewide vote, and President Trump’s December 18th executive order is simultaneously nudging Congress to revisit hemp-derived cannabinoids to preserve access to appropriate full-spectrum CBD. The line everyone is racing toward keeps moving.
🔎 What It Signals: This is the part that never shows up in a press conference. Someone is in a warehouse looking at pallets they bought in good faith. Someone is staring at a label order they cannot cancel. Someone is trying to explain to a bartender why the product that kept the lights on this month might be contraband next month. And out on the edge of town, there is a farmer at the kitchen table with a seed catalog and a spreadsheet, trying to decide what to plant in the spring without knowing whether the fall market will even exist. Ohio has three clocks running at once, a state compliance timeline, a referendum timeline, and a federal timeline that carries more weight once it becomes effective. When laws move like this, compliance turns into guesswork with invoices attached. The public risk is real, and broad rules that miss their target turn that risk into a wider credibility problem.
🧠 THC Group Take: Ohio is trying to solve a real problem: intoxicating products riding through weak retail with kid-friendly packaging and no meaningful enforcement. If the goal is to get candy knockoffs out of gas stations, then write the rule for that exact target and enforce it like you mean it. Broad definitions that catch everything do not read as public health to the public, they read as government swinging at the whole category because it could not separate the worst actors from the adults in the room.
The process has also made the market feel like it is built on quicksand. A court ruling narrows the executive lane. The legislature writes a statute. A beverage off-ramp appears. The governor vetoes it. A referendum campaign tries to freeze the whole thing. Then Washington signals it may preserve a full-spectrum CBD lane while still tightening intoxicating THC nationally. That sequence asks businesses to make expensive compliance choices with no confidence that the rule they are building toward will still exist when the product reaches the shelf.
Voters are not a separate species from consumers. They see the packaging. They see where the products are sold. They also see when lawmakers reach for a blunt instrument because it is easier than doing the hard work of drawing lines that hold up in court and in commerce. The durable path is precise rules that push intoxicating products into accountable channels, protect a disciplined low-dose model with real guardrails, and leave room for adults to make informed choices without pretending the category will disappear if the statute is strict enough.
Fast-moving headlines, flagged for what matters.
Trump’s December 18th executive order directs DOJ to complete the pending Schedule III rulemaking on an expedited track and assigns the White House legislative team to work with Congress on a statutory lane for hemp-derived cannabinoid products. The order does not change federal legality on its own, but it does change the posture inside government by attaching presidential urgency to a process that loves to drift. The hemp directive matters because Congress already narrowed the finished-product lane, and the next fight will define which products stay in lawful national commerce and which get pushed back into state-contained models. The hinge remains a final rule, an effective date, and the litigation sprint that follows publication. Plan for two parallel 2026 tracks, one focused on rescheduling and tax exposure, one focused on hemp definitions, guardrails, and enforcement lines. (StratCann)
Republican lawmakers are escalating opposition to rescheduling by focusing on 280E, arguing Schedule III would deliver meaningful tax relief to state-legal cannabis businesses. 280E remains in place until a final rule is adopted, published, and effective, so this is a timing fight as much as a policy fight. Expect pressure through hearings, letters, and appropriations language designed to slow implementation and harden the administrative record. Opponents are also building a courtroom script that targets accepted medical use and public-safety tradeoffs. Finance teams can model outcomes now, but cash planning still lives under today’s tax friction until the effective date survives court review. (Thomson Reuters Tax)
Two major nursing associations endorsed the rescheduling push, tying it to patient safety and stronger research access. The American Nurses Association emphasized evidence-informed care and a clearer federal posture for clinical decision-making. The American Association of Nurse Anesthesiology focused on perioperative care, including pain management and anesthesia interactions that demand better data. That support matters because it adds medical credibility to a debate opponents want framed as culture war. A final rule would give health systems and academic centers cleaner footing for protocols, IRB approvals, and federally compliant study design. (Marijuana Moment)
A former High Times chairman is urging lawmakers to pair reform with public health safeguards, with blunt attention to addiction risk and youth exposure. He supports rescheduling and expanded research, yet argues high-potency, frequent use can produce real dependency for a meaningful minority, even when harms build slowly. His asks are straightforward: unlock rigorous research, fund education and treatment, and require transparent consumer information on potency and risk. The argument lands at a moment when opponents will use addiction narratives to justify crackdowns that sweep disciplined low-dose models together with slapdash intoxicating retail. Reform that brings safeguards along for the ride gives policymakers cover to move forward and narrows the space for prohibition messaging to dominate the room. (USA Today)
Even if marijuana moves to Schedule III, federal firearms restrictions tied to “unlawful user” status remain in place because the underlying federal legality question stays unresolved. The statute does not turn on whether cannabis sits in Schedule I or Schedule III, and the executive order does not legalize state-law use under federal law. That keeps the Form 4473 problem live, with consumers exposed if they answer incorrectly and dealers exposed if they complete a sale with reason to believe a buyer is an unlawful user. Rescheduling could expand research and narrow 280E over time, yet it does not create a prescription framework for the products people are buying in state markets today. The practical result is continued legal uncertainty for patients and consumers who also want to own firearms until Congress or DOJ resolves the federal legality gap. (Guns.com)
Ohioans for Cannabis Choice filed an initial referendum petition to try to block a new law from taking effect and send the law back to voters. The law clamps down on intoxicating hemp, including THC beverages sold through bars and restaurants, and it also adds new penalties and use restrictions for adult-use marijuana that advocates call a rollback of the 2023 vote. The filing triggers reviews by Secretary of State Frank LaRose and Attorney General Dave Yost before the campaign can begin the 90-day sprint for 248,092 valid signatures. DeWine vetoed a temporary carveout that would have kept THC beverages in bars longer, so the fight now turns into a statewide signature operation with real cost and county distribution requirements. The near-term reality is a stop-start compliance calendar, with businesses planning around a law that could be paused before it reaches its effective date. (Cleveland.com, Columbus Dispatch)
Richmond breweries and hemp suppliers are still investing in THC cocktails and seltzers even after Congress rewrote the federal hemp definition to cap finished products at 0.4 milligrams of total THC per container, effective November 12, 2026. Virginia’s 2023 framework already pushed the category into a disciplined lane with low-dose limits, a CBD ratio pathway, a ban on synthetics, mandatory lab testing, and real penalties for batches that miss the mark. Many producers see the federal change as another compliance reset with runway and are betting state policy will keep governing the near term. The vulnerability is distribution and placement, since an ultra-low federal container cap can force products into state-contained programs or tightly controlled adult channels where age-gating and enforcement stay credible. VDACS says it will continue enforcing state law while it reviews the federal change, so every launch plan now runs with a visible deadline and thin tolerance for sloppy formulation. (Richmond Times-Dispatch)
Massachusetts regulators will begin reviewing cultivators at renewal to determine whether a licensee should be moved into a lower canopy tier based on sell-through, a concept contemplated since the earliest CCC regulations but never implemented at scale. The stated trigger is production that does not clear a sell-through threshold, yet the pressure point is whether implementation stays objective and equitable across business models. The policy can advantage vertically integrated operators who can move inventory internally in Metrc in ways independent cultivators cannot replicate with the same ease. Every cultivator also retains the option to voluntarily relegate to reduce fees or reset plans, which complicates any narrative about forced downsizing versus business choice. Renewal season now carries direct production downside, with tiering decisions shaped by data interpretation, internal transfers, and a regulator’s appetite for enforcement theater.. (Boston Globe)
The Massachusetts Senate advanced a sweeping reform package that restructures the Cannabis Control Commission and pushes the bill into conference with the House. The Senate version shrinks the CCC to three members, changes appointment mechanics, and tightens the executive chain in ways that will matter as soon as the agency has to make hard calls. It also lifts the retail license cap to four, adjusts how minority equity stakes are counted toward that limit, and removes the medical vertical integration requirement that has kept parts of the market structurally rigid. The Senate added a delivery provision that flips the default toward statewide delivery access unless a municipality secures a waiver, turning local control into an opt-out fight. Conference will decide whether Massachusetts ends the year with modernization that actually changes day-to-day operating reality or another paper rewrite that stalls on politics. (WWLP via State House News Service)
Western Massachusetts operators are sketching out cannabis cafes and lounge spaces after final social consumption regulations were approved, with an effective date slated for early January 2026 pending state process. Some owners see a needed on-ramp for adults who cannot consume at home and a way to diversify revenue as retail margins stay tight. Others see a high-capex bet with unclear local approvals, uncertain customer volume, and a compliance burden that looks closer to hospitality than retail. Municipal opt-in remains the gatekeeper, which means the first winners will be the teams that can build a public-facing safety case and win zoning support. The license may exist on paper for a while before it exists on the ground. (Daily Hampshire Gazette)
Maine Revenue Services issued a revised instructional bulletin on how sales and use tax applies to medical cannabis and related items sold by registered caregivers and dispensaries. The guidance clarifies that retail sales of cannabis, tinctures, topical treatments, edible products, and paraphernalia are taxed at the general rate, while prepared food containing cannabis is taxed at the prepared food rate. It also outlines exemptions for certain purchases tied to commercial agricultural production, manufacturing, and packaging materials. The risk is misclassification, since small product differences can trigger different rates and audit exposure. Expect operators to revisit POS tax mapping, menus, and sourcing documentation so the bulletin does not become a margin surprise. (Bloomberg Tax)
A Tennessee lawmaker is rolling out a 2026 bill that would allow one adult per household to grow up to 15 marijuana plants at home, split across adult, intermediate, and budding stages. The proposal keeps sales and distribution illegal and frames the policy as personal supply without taxes. It also builds enforcement into the front end through certification cards, a seed co-op concept, and permanent disqualification for violations. The sponsor is leaning on Trump’s Schedule III executive order as political cover, even though rescheduling does not legalize marijuana in Tennessee. The bill sets up an intraparty test in a prohibition state, with home grow framed as freedom and the compliance leash written directly into the text. (Action News 5)
HempToday’s 2025 investment review describes a market where capital moved from optimism to triage, rewarding regulatory clarity and industrial use cases while walking away from hype. High-profile initiatives faded quietly, reinforcing tougher diligence standards around execution risk and believable revenue paths. The money that did show up clustered around processing infrastructure, regulated medical channels, and regionally coordinated strategies that can survive policy shifts. Europe’s activity leaned toward medical and industrial exposure rather than recreational adjacency, showing where institutional comfort still lives. 2026 looks like a narrower field, with serious projects priced like manufacturing and everything else treated like a science project. (HempToday)
The UAE adopted a new federal framework that legalizes tightly controlled industrial hemp activity and permits hemp compounds in authorized medical products under a licensing regime. The rules keep consumer intoxication off the table by restricting personal and recreational use and excluding categories like foods, dietary supplements, smoking products, and veterinary products. Cosmetics remain prohibited except for limited seed and stalk oil uses and any narrower exceptions set by Cabinet decision. The structure relies on permits for cultivation, manufacturing, and trade and embeds security and agency approvals into the pathway. The message is simple: the UAE wants compliant industrial and medical supply chains and is keeping mass consumer cannabinoid commerce outside the lane. (Ganjapreneur)
Idaho’s attorney general joined other states in opposing the rescheduling directive while the state’s two U.S. senators signed a separate GOP letter urging Trump to keep marijuana in Schedule I. The substance is familiar, focused on youth exposure, impaired driving, and agency overreach, but the purpose is strategic: build a record for oversight, appropriations pressure, and a court fight the moment a final rule publishes. For prohibition states, this is also local positioning, a way to show resistance even if Washington moves forward. The practical effect is more process risk, since every letter and statement becomes future litigation oxygen. The market still lives on one date, the effective date, and opponents are organizing to make that date arrive late or not at all. (Seattle Red; Idaho Statesman)
Kansas Republicans are publicly divided after Trump’s December 18th executive order directing DOJ to move faster on the Schedule III process. A state senator condemned the move as politics and money, while Kansas Cannabis Coalition leaders framed it as a reckoning for lawmakers who have held to prohibition posture. The dynamic is familiar in red states, where federal movement gives permission for voters to applaud change while elected officials work to stay aligned with party instincts. One correction matters: rescheduling would not automatically reduce tax burdens for CBD shops and it does not legalize marijuana in Kansas. The pressure in 2026 will be legislative, with advocates using federal momentum to force a state choice on whether Kansas keeps watching from the sideline. (KSNT)
Learn AI in 5 minutes a day
What’s the secret to staying ahead of the curve in the world of AI? Information. Luckily, you can join 1,000,000+ early adopters reading The Rundown AI — the free newsletter that makes you smarter on AI with just a 5-minute read per day.
From the hearing room to the comment section — we’re watching it all.
🧩 Vireo’s Eaze deal is a reminder that the next growth cycle is going to reward reach and distribution, not just cultivation scale. Buying a delivery platform and an existing retail footprint in California and Florida compresses years of market entry work into one transaction, and it forces smaller brands to compete against route density and customer access. (Ganjapreneur)
🛠️ A Cannatrol outlook memo is a clean signal of where capex is actually moving: retrofits, drying and curing control, and post-harvest consistency work that protects margins when flower pricing stays compressed. If Schedule III momentum holds, the first winners will still be operators who can prove repeatable quality and defend inputs and yields in diligence, since capital will chase discipline before it chases scale. (StreetInsider)
🌍 High Times argues 2025 marked a quiet global shift toward regulating cannabis through its interfaces, paraphernalia, imagery, chemistry, and product definitions, with governments tightening control without owning a full legalization debate. The U.S. example is the November hemp definition rewrite, a technical move with 2026 consequences that pushes intoxicating finished products toward narrower, enforceable channels while leaving disciplined models to prove their case under real guardrails. (High Times)